{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:28:17Z","timestamp":1790188097083,"version":"4.1.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018536","name":"National Mega Project on Major Infectious Disease Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018536","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018536","name":"National Mega Project on Major Infectious Disease Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018536","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chikungunya fever is an acute infectious disease that is mediated by the mosquito-transmitted chikungunya virus (CHIKV), for which no licensed vaccines are currently available. Here, we explored several immunization protocols and investigated their immunity and protective effects in mice, with DNA- and virus-like particle (VLP)- vaccines, both alone and in combination. Both DNA and VLP vaccine candidates were developed and characterized, which express CHIKV structural genes (C-E3-E2-6K-E1). Mice were immunized twice, with different protocols, followed by immunological detection and CHIKV Ross challenge. The highest antigen-specific IgG and neutralizing activity were induced by DNA and VLP co-immunization, while the highest cellular immunity was induced by DNA vaccination alone. Although all vaccine groups could protect mice from lethal CHIKV challenge, demonstrated as reduced viral load in various tissues, without weight loss, mice co-immunized with DNA and VLP exhibited the mildest histopathological changes and lowest International Harmonization of Nomenclature and Diagnostic Criteria (INHAND) scores, in comparison to mice with either DNA or VLP vaccination alone. We concluded that co-immunization with DNA and VLP is a promising strategy to inducing better protective immunity against CHIKV infection.<\/jats:p>","DOI":"10.3389\/fimmu.2021.655743","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T06:05:33Z","timestamp":1616565933000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice"],"prefix":"10.3389","volume":"12","author":[{"given":"Zhimin","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peihua","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingdong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leiliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/CMR.00104-16","article-title":"Vaccine and therapeutic options to control chikungunya virus","volume":"31","author":"Powers","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1574149","article-title":"51 years in of Chikungunya clinical vaccine development: A historical perspective","volume":"15","author":"Reyes-Sandoval","year":"2019","journal-title":"Hum Vaccines Immunother"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw271","article-title":"Development of Vaccines for Chikungunya Fever","volume":"214","author":"Erasmus","year":"2016","journal-title":"J Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/prca.201700020","article-title":"Ubiquitin-Conjugating Enzyme E2 L3 is Downregulated by the Chikungunya Virus nsP2 Protease","volume":"12","author":"Ramphan","year":"2018","journal-title":"Proteomics - Clin Appl"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00814-13","article-title":"Cross-Inhibition of Chikungunya Virus Fusion and Infection by Alphavirus E1 Domain III Proteins","volume":"87","author":"Sanchez-San Martin","year":"2013","journal-title":"J Virol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02792-15","article-title":"Dissecting the Role of E2 Protein Domains in Alphavirus Pathogenicity","volume":"90","author":"Weger-Lucarelli","year":"2016","journal-title":"J Virol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002124","article-title":"Effective Chikungunya Virus-like Particle Vaccine Produced in Insect Cells","volume":"7","author":"Metz","year":"2013","journal-title":"PloS Negl Trop Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nature09546","article-title":"Structural changes of envelope proteins during alphavirus fusion","volume":"468","author":"Li","year":"2010","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.02881","article-title":"Recent Progress in Vaccine Development Against Chikungunya Virus","volume":"10","author":"Gao","year":"2019","journal-title":"Front Microbiol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-020-09159-z","article-title":"Recent advances in therapeutic applications of neutralizing antibodies for virus infections : an overview","volume":"68","author":"Ali","year":"2020","journal-title":"Immunol Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61185-5","article-title":"Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: A phase 1 dose-escalation trial","volume":"384","author":"Chang","year":"2014","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32488-7","article-title":"Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial","volume":"392","author":"Reisinger","year":"2018","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-20305-4","article-title":"Antibody-mediated enhancement aggravates chikungunya virus infection and disease severity","volume":"8","author":"Lum","year":"2018","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01926-14","article-title":"Prime-Boost Immunization Strategies against Chikungunya Virus","volume":"88","author":"Hallengard","year":"2014","journal-title":"J\u00a0Virol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/vaccines7010002","article-title":"Attenuation and Stability of CHIKV-NoLS, a Live-Attenuated Chikungunya Virus Vaccine Candidate","volume":"7","author":"Abeyratne","year":"2019","journal-title":"Vaccines"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0004782","article-title":"Expression and Characterization of Yeast Derived Chikungunya Virus Like Particles (CHIK-VLPs) and Its Evaluation as a Potential Vaccine Candidate","volume":"10","author":"Saraswat","year":"2016","journal-title":"PloS Negl Trop Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1089\/vim.2012.0061","article-title":"Nonstructural protein 2 (nsP2) of chikungunya virus (CHIKV) enhances protective immunity mediated by a CHIKV envelope protein expressing DNA vaccine","volume":"26","author":"Bao","year":"2013","journal-title":"Viral Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/jgm","article-title":"Enhanced contraceptive response by co-immunization of DNA and protein vaccines encoding the mouse zona pellucida 3 with minimal oophoritis in mouse ovary","volume":"9","author":"Li","year":"2012","journal-title":"J Gene Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2007.05.013","article-title":"Co-immunization with West Nile DNA and inactivated vaccines provides synergistic increases in their immunogenicities in mice","volume":"9","author":"Ishikawa","year":"2007","journal-title":"Microbes Infect"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.07.016","article-title":"Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis","volume":"110","author":"Hwang","year":"2014","journal-title":"Antiviral Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/mBio.00405-13","article-title":"Reovirus cell entry requires functional microtubules","volume":"4","author":"Mainou","year":"2013","journal-title":"MBio"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/JVI.01747-18","article-title":"Fatty Acid Synthase Promotes the Palmitoylation of Chikungunya Virus nsP1","volume":"93","author":"Zhang","year":"2019","journal-title":"J Virol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.1673-4092.2019.05.013","article-title":"Construction and identification of Chikungunya virus infectious clones","volume":"26","author":"Luo","year":"2018","journal-title":"Int J Viro"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.14.8828","article-title":"A Human T-Cell Leukemia Virus Type 1 Regulatory Element Enhances the Immunogenicity of Human Immunodeficiency Virus Type 1 DNA Vaccines in Mice and Nonhuman Primates","volume":"79","author":"Barouch","year":"2005","journal-title":"J Virol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-3618-2","article-title":"Chapter 25 Neutralization Assay for Chikungunya Virus Infection : Plaque Reduction Neutralization Test","volume":"1426","author":"Azila","year":"2016","journal-title":"Methods Mol Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00504-19","article-title":"Infectious Chikungunya Virus (CHIKV) with a Complete Capsid Deletion: a New Approach for a CHIKV Vaccine","volume":"93","author":"Zhang","year":"2019","journal-title":"J Virol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.02.063","article-title":"Humoral and cellular immunity against both ZIKV and poxvirus is elicited by a two-dose regimen using DNA and non-replicating vaccinia virus-based vaccine candidates","volume":"37","author":"Zhan","year":"2019","journal-title":"Vaccine"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.03.060","article-title":"Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus","volume":"26","author":"Muthumani","year":"2008","journal-title":"Vaccine"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.03418-13","article-title":"Esteban M. A Novel Poxvirus-Based Vaccine, MVA-CHIKV, Is Highly Immunogenic and Protects Mice against Chikungunya Infection","volume":"88","author":"Garcia-Arriaza","year":"2014","journal-title":"J\u00a0Virol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-3035-9","article-title":"A single-dose live- attenuated YF17D-vectored SARS-CoV-2 vaccine candidate","volume":"590","author":"Sanchez-Felipe","year":"2020","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.09.045","article-title":"Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits","volume":"31","author":"Metz","year":"2013","journal-title":"Vaccine"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0007316","article-title":"Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice","volume":"13","author":"Ar\u00e9valo","year":"2019","journal-title":"PloS Negl Trop Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02603-09","article-title":"Chikungunya Virus Arthritis in Adult Wild-Type Mice","volume":"84","author":"Gardner","year":"2010","journal-title":"J Virol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.antiviral.2017.04.009","article-title":"Coinjection of a vaccine and anti-viral agents can provide fast-acting protection from foot-and-mouth disease","volume":"143","author":"You","year":"2017","journal-title":"Antiviral Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/00029330-200802010-00008","article-title":"SSB peptide and DNA co-immunization induces inhibition of anti-dsDNA antibody production in rabbits","volume":"121","author":"Min","year":"2008","journal-title":"Chin Med J (Engl)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.04.037","article-title":"HIV \/ SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques","volume":"31","author":"Li","year":"2013","journal-title":"Vaccine"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1102828","article-title":"Caveolin-1\u2013Mediated Negative Signaling Plays a Critical Role in the Induction of Regulatory Dendritic Cells by DNA and Protein Coimmunization","volume":"189","author":"Li","year":"2012","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep07771","article-title":"Co-immunization with DNA and protein mixture: A safe and efficacious immunotherapeutic strategy for Alzheimer\u2019s disease in PDAPP mice","volume":"5","author":"Liu","year":"2015","journal-title":"Sci Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.113777","article-title":"Antiviral drug discovery against arthritogenic alphaviruses : Tools and molecular targets","volume":"174","author":"Abdelnabi","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.07.054","article-title":"Chimeric alphavirus vaccine candidates for chikungunya","volume":"26","author":"Wang","year":"2008","journal-title":"Vaccine"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000928","article-title":"A DNA vaccine against Chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates","volume":"5","author":"Mallilankaraman","year":"2011","journal-title":"PloS Negl Trop Dis"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw111","article-title":"Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus","volume":"214","author":"Muthumani","year":"2016","journal-title":"J\u00a0Infect Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1086\/600381","article-title":"Prophylaxis and therapy for chikungunya virus infection","volume":"200","author":"Couderc","year":"2009","journal-title":"J Infect Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.655743\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T06:05:37Z","timestamp":1616565937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.655743\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,24]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2021.655743"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.655743","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,24]]},"article-number":"655743"}}